We have recently seen a case of large diffuse B-cell lymphoma of probable folicular origin (CD10+ partial expressión) with a well defined CD103 expression by B-cells. The references in the literature are scanty and unclear.
I also found a CD103+ monoclonal B-cell population in bone marrow. The patient was diagnosed with DLBCL in intestine. We didn't get the biopsy for immunophenotyping but the pathologist has defined it as such. In the bone marow the cells are rather small.
This finding of aberant CD 103 expression /biomarker of Treg cells/ in DLBCL is of unknown significance. However, pathologist never use CD103 as routine biomarker when they see DLBCL, so if we perform CD103 examination in tissue samples God knows how many cases we could be able to find. On the other side I personally think this would be a rare phenomenon. Aberant expressions of biomarkers are usual phenomena, especially in acute leukemias. Well known is that HCL express this biomarker,perhaps your case might be in some correlation with HCL-for example transformation of HCL into DLBCL, or mixed lineage B cell lymphoma. On the end this your finding is quite interesting, and it opens a new aspects for new hypothesis for new researches. If you have not publish this finding do so.
Jordi Juncà We have just analyzed a patient with a previous diagnosis of follicular lymphoma in the lymph node that returned to the hospital with adenopathies and abnormal lymphocytes in the blood. We performed immunophenotyping of the blood and found 12% of medium-sized cells with characteristics of follicular lymphoma: CD19 weak, CD10++, BCL-2++, CD5 neg, CD43 neg, and IgM neg. However, these cells showed some positivity for post-germinal markers such as CD27, CD11c, and CD39. In addition, 50% of the abnormal population showed expression of CD103 (without expression of CD25, CD123, or LAIR-1). It is the first time I see CD103 expression in a follicular lymphoma. On the other hand, I´ve already seen cases of hairy cell leukemia (very classic) with CD10 expression.